VS 01

Drug Profile

VS 01

Alternative Names: VS-01

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Versantis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inborn urea cycle disorders; Liver failure

Most Recent Events

  • 13 Jul 2016 Preclinical trials in Inborn urea cycle disorders in Switzerland (Intraperitoneal)
  • 13 Jul 2016 Preclinical trials in Liver failure in Switzerland (Intraperitoneal)
  • 17 May 2016 VS 01 receives Orphan Drug status for Liver failure in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top